Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Energy Services of America issued a press release on August 10, 2026, disclosing its results of operations and financial condition for the three and nine months ended June 30, 2026. The filing reports quarterly financial results including revenue of $130.0 million (25.5% YoY increase), net income of $3.3 million ($0.18 per diluted share), and a 33% increase in quarterly dividend. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and capital allocation decisions.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
AECOM disclosed its third quarter fiscal 2026 financial results via press release on August 10, 2026, as required under Item 2.02. The filing includes quarterly revenue ($3.6 billion), operating loss ($76 million GAAP), net loss ($84 million), and diluted EPS ($-0.65), along with updated full-year guidance reflecting a $337 million pre-tax charge on a Construction Management project. This is a standard quarterly earnings release with material financial impacts warranting investor disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
This is a clear earnings release disclosing Hallador's second quarter 2026 financial and operating results. The filing explicitly states "On August 10, 2026, Hallador Energy Company issued a press release announcing its second quarter 2026 financial and operating results," with the press release attached as Exhibit 99.1. The exhibit contains detailed financial summaries including revenue ($101.5M), net loss ($15.2M), and adjusted EBITDA ($2.9M loss), along with operational highlights and forward guidance. This is material to investors as it reflects the company's quarterly earnings performance and strategic project updates.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a quarterly earnings release for Q2 2026 disclosing financial and operating results for the period ended June 30, 2026. The press release (Exhibit 99.1) provides comprehensive financial highlights including pounds drummed, shipped, and sold; product sales revenue of $14.4 million; cash position of $95.3 million; and cash cost per pound metrics. The filing is made under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases, and includes a conference call announcement for discussion of quarterly results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
WhiteHorse Finance issued a press release on August 10, 2026 announcing its financial results for the second quarter ended June 30, 2026, including net investment income of $4.681 million ($0.217 per share), net asset value per share of $11.77, portfolio fair value of $569.2 million, and a declared quarterly distribution of $0.25 per share.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure announces financial results including revenue of $32.9 million (down 2%), net income of $4.0 million or $0.25 per diluted share (down from $5.2 million or $0.32 in Q2 2025), and detailed segment performance. The press release is furnished as Exhibit 99.1 and includes management commentary on operational performance and forward guidance, which is typical of earnings releases material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-10
Item 2.02
Coronado Global Resources disclosed its H1 2026 financial results on August 10-11, 2026, reporting revenue of US$981 million, a net loss of US$418 million, and an adjusted EBITDA loss of US$83 million, along with operational highlights and forward guidance for 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 75%
filed 2026-08-10
Item 2.02
The Item 2.02 disclosure reports Cherry Hill's second quarter 2026 financial results, including GAAP net income of $1.3 million ($0.04 per share), earnings available for distribution of $5.5 million ($0.15 per diluted share), and book value of $3.16 per share. While the press release also announces a merger agreement with TPG Mortgage Investment Trust, the Item 2.02 section itself is focused on quarterly results disclosure, which is the primary earnings release event. The merger is a separate material event but is not the focus of Item 2.02 specifically.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Item 2.02 discloses Motorcar Parts of America's fiscal 2027 first quarter earnings results for the period ended June 30, 2026, with a press release furnished as Exhibit 99.1. The filing reports net sales of $168.0 million, a net loss of $13.4 million ($0.71 per share), and includes consolidated financial statements, balance sheet data, and management commentary on results and full-year guidance reaffirmation. This is a standard quarterly earnings release material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Lincoln Educational Services issued a press release on August 10, 2026, announcing Q2 2026 financial results with revenue of $142.6 million (up 22.4%) and Adjusted EBITDA of $12.7 million (up 42.4%), while reiterating full-year 2026 financial guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a standard earnings release disclosing Q2 2026 financial results for Nu Skin Enterprises. The Item 2.02 filing announces revenue of $320.1 million (down 17.1% YoY), EPS of $(5.14) (or $0.20 adjusted), and provides Q3 and full-year 2026 guidance. The press release includes detailed consolidated financial statements, segment revenue breakdowns, and customer metrics, which are typical components of a quarterly earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
This is a classic Item 2.02 earnings release disclosing Rocket Pharmaceuticals' second quarter 2026 financial results for the period ended June 30, 2026. The filing includes detailed financial metrics (R&D expenses of $29.5M, G&A expenses of $17.4M, net income of $123.2M, cash position of $283.7M, and cash runway guidance into Q2 2028), along with operational highlights including FDA approval of KRESLADI, a $180M Priority Review Voucher sale, and clinical progress updates. The press release is furnished as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-10
EX-99.1
This is a press release announcing Alcon's second-quarter 2026 financial results, including net sales of $2.8 billion (up 8% reported, 7% constant currency), core diluted EPS of $0.84 (up 11%), and updated full-year 2026 guidance with raised core operating margin and core diluted EPS growth expectations. The document explicitly states "reported its financial results for the three and six month periods ending June 30, 2026" and includes detailed segment performance, cash flow metrics, and forward guidance—all hallmarks of a quarterly earnings release.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-08-10
EX-99.1
This is a press release announcing Standard Lithium's "Second Quarter 2026 Results" for the three and six-month periods ended June 30, 2026. The document discloses financial metrics (cash of $137.3 million, working capital of $137.1 million, no debt as of June 30, 2026) and operational highlights, and explicitly states "This news release should be read in conjunction with the Company's Consolidated Financial Statements and MD&A." While the release emphasizes operational milestones (NEPA approval, construction contracts, demonstration plant achievements), the primary purpose is to report quarterly financial and operating results, making it an earnings release. The material operational progress on the SWA Project (FID pathway, major regulatory clearance) reinforces materiality to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
PennantPark Investment Corporation issued a press release on August 10, 2026, announcing financial results for the third quarter ended June 30, 2026. The disclosure includes detailed operating results (net investment income of $8.9 million, net realized gains of $12.0 million), portfolio metrics (total assets of $1,193.2 million, net asset value per share of $6.56), and distributions declared per share. This is a standard quarterly earnings release furnished under Item 2.02, which is material to investors assessing the company's financial performance and dividend sustainability.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
PennantPark Floating Rate Capital Ltd. issued a press release on August 10, 2026 announcing its financial results for the third fiscal quarter ended June 30, 2026. The disclosure includes comprehensive quarterly financial highlights (net assets, NAV per share, investment income, net investment income per share, distributions declared), portfolio activity, and detailed results of operations. This is a standard quarterly earnings release furnished under Item 2.02, with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-10
EX-99.1
This is a press release announcing monday.com's second quarter 2026 financial results, including revenue of $364.6 million (22% YoY growth), GAAP and non-GAAP operating metrics, net income per share, and forward guidance for Q3 and full-year 2026. The exhibit contains condensed consolidated financial statements and detailed business metrics (ARR, net dollar retention, customer counts). This is a classic earnings release disclosing quarterly financial results, material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-10
EX-99.1
This is a press release announcing Perion Network's second quarter 2026 financial results, including revenue of $98.2 million, net loss of $6.8 million (GAAP), and adjusted EBITDA of $2.8 million. The document explicitly states "Perion Reports Second Quarter 2026 Results" and includes consolidated statements of operations, balance sheets, and cash flows for the periods ended June 30, 2026. The company also narrowed its full-year 2026 guidance, which is material to investors assessing the registrant's financial trajectory.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-10
This is a press release announcing Camtek's Q2 2026 financial results, including record revenues of $133.2 million, GAAP net income of $23.3 million, and forward guidance for Q3 and H2-26. The release includes detailed financial statements (balance sheet, income statement, and GAAP-to-non-GAAP reconciliation) and management commentary on business performance and outlook. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-10
EX-99.1
Nayax reported second quarter 2026 financial results with revenue of $122.6–$123 million (28% year-over-year growth), net loss of $10.1 million, and Adjusted EBITDA of $14.1 million (12% growth). The company reaffirmed full-year 2026 guidance and disclosed key operational metrics including recurring revenue of $87.7 million (24% growth).
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-08-10
This is a monthly revenue announcement disclosing July 2026 consolidated revenue of NT$2,823.0 million (US$87.5 million), representing a 43.6% year-over-year increase and a record high monthly revenue since 2014. The press release explicitly states "ChipMOS REPORTS 43.6% YoY INCREASE IN JULY 2026 REVENUE" and notes strong AI-related demand driving the results. While monthly revenue disclosures are less common than quarterly earnings, this announcement of material revenue growth and record performance would affect a reasonable investor's assessment of the company's operational momentum and financial health.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
This is a classic earnings release disclosure under Item 2.02. The press release announces "financial results for its fiscal 2026 third quarter ended June 30, 2026" with specific financial metrics including R&D expenses, G&A expenses, operating loss, net loss per share, and balance sheet information (cash position). The filing explicitly states the press release is "furnished pursuant to Item 2.02 of Form 8-K" and is attached as Exhibit 99.1, which is the standard format for quarterly earnings announcements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
CECO Environmental issued a press release on August 10, 2026 announcing its financial results for the second quarter ended June 30, 2026, including revenue of $285.0 million (up 54%), net loss of $(34.8) million, and adjusted EBITDA of $40.2 million (up 73%). The company also raised its full-year 2026 consolidated outlook. This is a standard quarterly earnings disclosure furnished under Item 2.02 with consolidated financial statements and reconciliations of GAAP to non-GAAP measures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-10
Item 2.02
Axsome issued a press release on August 10, 2026 announcing Q2 2026 financial results, disclosing total net product revenue of $218.4 million (46% YoY growth), with AUVELITY sales of $180.3 million (51% YoY growth), SUNOSI revenue of $35.8 million (20% YoY growth), SYMBRAVO revenue of $2.3 million, and a net loss of $51.3 million. The disclosure includes detailed commercial metrics, operating expenses, cash position, and forward-looking guidance on cash sufficiency.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Village Farms issued a press release on August 10, 2026 announcing its financial results for Q2 2026 ended June 30, 2026, disclosing consolidated net sales of $64 million (27% sequential, 7% YoY growth), net income of $7.1 million, and record cannabis revenues of $53.5 million. The filing explicitly states this is furnished under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases on Form 8-K.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure explicitly states that "Jade Biosciences, Inc. (the 'Company') issued a press release announcing the Company's financial results for the quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated financial statements (balance sheet and statement of operations) showing Q2 2026 results including net loss of $55.8 million, R&D expenses of $50.1 million, and cash position of $461.2 million, along with a corporate update on pipeline progress.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-10
EX-99.1
This is a press release announcing Sohu.com's unaudited financial results for the second quarter ended June 30, 2026. The document discloses total revenues of US$136 million (up 7% YoY), net income of US$0.2 million (GAAP) and US$0.5 million (non-GAAP), along with detailed segment results, balance sheet data, and forward guidance for Q3 2026. The filing includes condensed consolidated statements of operations and balance sheets, making it a classic quarterly earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-08-10
Item 8.01
The Company issued a press release announcing topline results from its Phase 3 LEVEL clinical trial of TNX-103. Although the primary endpoint was not met (6-minute walk distance improvement), the disclosure of Phase 3 trial results—a major clinical milestone for a development-stage pharmaceutical company—constitutes a material event comparable to an earnings release in terms of investor significance. The results include detailed efficacy, safety, and biomarker data that would materially affect investor assessment of the drug candidate's viability and the company's regulatory path forward.
View raw filing on EDGAR →
8-K
Earnings release
confidence 75%
filed 2026-08-10
Item 2.02
The Item 2.02 disclosure centers on Apogee's second quarter 2026 financial results, including cash position ($1.3 billion), R&D expenses ($67.3 million), G&A expenses ($24.3 million), and net loss ($85.9 million), furnished as a press release exhibit. While the press release also announces the pending AbbVie acquisition ($135.11/share, ~$10.9 billion equity value), the Item 2.02 classification specifically addresses financial results. The acquisition is material but constitutes a separate M&A event; however, since Item 2.02 is explicitly designated for "Results of Operations and Financial Condition," the earnings_release classification is most appropriate for this Item, though the filing also contains ma_activity elements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
The filing discloses Silence Therapeutics' second quarter 2026 financial and business results via a press release issued on August 10, 2026. The Item 2.02 disclosure includes condensed consolidated statements of operations and balance sheets showing Q2 2026 results (net loss of $12.3 million, R&D expenses of $9.1 million, cash position of $72.1 million) compared to prior-year periods, along with business highlights on clinical programs. This is a standard quarterly earnings release material to investors assessing the company's financial condition and operational progress.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-08-10
Item 7.01
Silence Therapeutics announced positive Phase 2 SANRECO trial results for divesiran in polycythemia vera on August 10, 2026, meeting primary and secondary endpoints with strong efficacy and safety profiles. The disclosure includes trial outcomes, safety findings, and plans for Phase 3 initiation, representing a material clinical milestone for the clinical-stage biotech company.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
This is a clear earnings release disclosing Q2 2026 financial results for the three and six months ended June 30, 2026. The filing explicitly states "Heron Therapeutics Announces Second Quarter 2026 Financial Results" and provides detailed net revenue performance by product line, cash position, and operational highlights. The withdrawal of full-year 2026 guidance and discussion of strategic alternatives add material context, but the core disclosure is the quarterly earnings announcement furnished as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
The filing discloses Cogent Biosciences' financial results for the second quarter ended June 30, 2026, via a press release attached as Exhibit 99.1. The disclosure includes condensed consolidated statements of operations showing Q2 2026 net loss of $96.4 million versus $73.5 million in Q2 2025, along with balance sheet data and detailed business highlights regarding clinical trial progress and regulatory milestones for bezuclastinib. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
Bowman Consulting Group Ltd. disclosed financial results for Q2 2026 ended June 30, 2026 via press release on August 10, 2026, reporting gross contract revenue of $146.1M (+19.7%), net service billing of $129.0M (+19.4%), and backlog of $658.7M (+50.3%).
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
Medical Properties Trust issued a press release on August 10, 2026 announcing financial results for the three and six months ended June 30, 2026, including net loss of ($0.01) per share and NFFO of $0.15 per share for Q2 2026, with consolidated balance sheets, income statements, and FFO reconciliations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Septerna disclosed its Q2 2026 financial results on August 10, 2026, including revenue of $26.7 million, R&D expenses of $35.1 million, net loss of $13.0 million, and cash position of $516.5 million. The filing includes a press release (Exhibit 99.1) announcing quarterly financial results and business highlights, which is the hallmark of an earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 10, 2026. The Item 2.02 disclosure explicitly states "Gaia, Inc. (the 'Company') issued a press release announcing results for its quarter ended June 30, 2026," with the full press release attached as Exhibit 99.1. The exhibit contains detailed financial results including revenue ($23.3M vs $24.6M YoY), net loss ($3.0M vs $1.8M YoY), and cash flow metrics, along with management commentary and condensed consolidated financial statements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including net loss of $63.2 million, R&D and G&A expenses, cash position of $461.1 million, and operating metrics. The filing also reports material clinical progress (OPERA-01 enrollment completion, OP-3136 Phase 1 data, Bayer collaboration), which are typical components of a biopharmaceutical company's earnings disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
This is a press release announcing Vera Therapeutics' second quarter 2026 financial results, including net loss of $109.5 million and net loss per share of $1.52, along with cash position and operating cash flow metrics. The disclosure is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The material business updates regarding TRUTAKNA's FDA accelerated approval and commercial launch are presented alongside the financial results, making this a comprehensive earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a clear earnings release for Enanta Pharmaceuticals' fiscal third quarter ended June 30, 2026. The Item 2.02 disclosure explicitly states "Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended June 30, 2026," with the full press release furnished as Exhibit 99.1. The exhibit contains detailed financial results including revenue ($14.4 million), operating expenses, net loss ($19.5 million), and cash position ($211.5 million), along with operational updates on clinical programs. This is a standard quarterly earnings announcement material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
This is a clear earnings release disclosing Fractyl Health's second quarter 2026 financial results, including R&D expenses ($13.8M), SG&A expenses ($5.3M), net loss ($25.5M), adjusted EBITDA (negative $16.3M), and cash position ($47.1M). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The disclosure includes both financial metrics and material clinical/business updates regarding the company's Revita and Rejuva programs.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a clear earnings release disclosing Entravision's financial results for Q2 2026 and the six-month period ended June 30, 2026. The press release, furnished as Exhibit 99.1, reports consolidated net revenue of $227.9 million (up 126% YoY), segment operating profit of $36.7 million, and net income of $19.7 million for Q2 2026, along with detailed segment performance metrics and balance sheet information. The disclosure is material as it provides comprehensive quarterly financial results affecting investor assessment of the company's operational and financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
The filing discloses Beachbody's financial results for Q2 2026 (quarter ended June 30, 2026) via a press release attached as Exhibit 99.1. The disclosure includes detailed revenue ($49.6M), operating income ($1.7M), net income ($1.4M), and Adjusted EBITDA ($6.7M) figures, along with operational metrics and forward guidance for Q3 2026. This is a standard quarterly earnings announcement material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Shimmick Corporation issued a press release on August 10, 2026 announcing financial results for Q2 2026 ended July 3, 2026, disclosing revenue of $107 million, gross margin of $12 million, net loss of $5 million, and Adjusted EBITDA of $4 million. The filing explicitly states this is an earnings release furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for quarterly earnings disclosures. The release includes detailed financial tables, segment performance analysis, and updated full-year 2026 guidance, all hallmarks of a quarterly earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
This is a clear earnings release disclosing Sana Biotechnology's financial results for Q2 2026 (quarter ended June 30, 2026), filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) reports GAAP and non-GAAP financial metrics including cash position ($160.5M), R&D expenses ($30.7M for Q2), net loss ($63.6M for Q2), and operating cash burn, along with business highlights on clinical program progress. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational progress.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
GEN Restaurant Group issued a press release on August 10, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $55.7 million, net loss of $(4.6) million, and other key financial metrics. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is material to investors assessing the company's financial performance and operational trends.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a straightforward earnings release for Q2 2026 financial results. The 8-K Item 2.02 discloses quarterly revenue of $29.4 million (82% YoY growth), gross margin of 60%, operating loss of $13.5 million, and net loss of $13.2 million, along with full-year 2026 revenue guidance of $116–$120 million. The press release is attached as Exhibit 99.1 and includes detailed financial statements and operational highlights. This is material to investors assessing the registrant's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-10
Item 2.02
Greystone Housing Impact Investors LP disclosed its financial results for the second quarter ended June 30, 2026, including a net loss of $1.52 million per BUC, Cash Available for Distribution of $0.10 per BUC, and total assets of $1.39 billion, with condensed consolidated statements of operations comparing Q2 2026 to Q2 2025 and six-month periods.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a clear earnings release disclosing Definitive Healthcare's Q2 2026 financial results for the quarter ended June 30, 2026. The press release, furnished as Exhibit 99.1, presents key financial metrics including revenue ($55.2M), net loss, adjusted net income, adjusted EBITDA, and cash flow, along with forward guidance for Q3 and full-year 2026. The Item 2.02 disclosure and attached press release are the hallmark of an earnings announcement, which is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02. The disclosure includes condensed financial statements (balance sheet and statements of operations), cash position ($120.7 million), R&D and G&A expenses, net loss per share ($0.73), and business updates regarding the MGX-001 hemophilia A program. The press release is furnished as Exhibit 99.1 and contains both financial results and operational milestones typical of an earnings announcement.
View raw filing on EDGAR →